Literature DB >> 16091743

The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene.

Jean-Sébastien Annicotte1, Carine Chavey, Nadège Servant, Jacques Teyssier, Aurélie Bardin, Anne Licznar, Eric Badia, Pascal Pujol, Françoise Vignon, Thierry Maudelonde, Gwendal Lazennec, Vincent Cavailles, Lluis Fajas.   

Abstract

Liver receptor homolog-1 (LRH-1) is a nuclear receptor previously known to have distinct functions during mouse development and essential roles in cholesterol homeostasis. Recently, a new role for LRH-1 has been discovered in tumor progression, giving LRH-1 potential transforming functions. In order to identify critical factors stimulating LRH-1 expression leading to deregulated cellular proliferation, we studied its expression and its regulation in several breast cancer cell lines. We observed that LRH-1 expression was increased in estrogen receptor (ER) alpha expressing cell lines, whereas weak-to-no expression was found in nonexpressing ERalpha cell lines. In MCF7, LRH-1 expression was highly induced after treatment with 17beta-estradiol (E2). This transcriptional regulation was the result of a direct binding of the ER to the LRH-1 promoter, as demonstrated by gelshift and chromatin immunoprecipitation assays. Interestingly, siRNA-mediated inactivation of LRH-1 decreased the E2-dependent proliferation of MCF7 cells. Finally, LRH-1 protein expression was detected by immunohistochemistry in tumor cells of human mammary ductal carcinomas. Altogether, these data demonstrate that LRH-1 is transcriptionally regulated by the ER alpha and reinforce the hypothesis that LRH-1 could exert potential oncogenic effects during breast cancer formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091743      PMCID: PMC2259230          DOI: 10.1038/sj.onc.1208950

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  A unified nomenclature system for the nuclear receptor superfamily.

Authors: 
Journal:  Cell       Date:  1999-04-16       Impact factor: 41.582

2.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.

Authors:  E Neuman; M H Ladha; N Lin; T M Upton; S J Miller; J DiRenzo; R G Pestell; P W Hinds; S F Dowdy; M Brown; M E Ewen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.

Authors:  M D Planas-Silva; R A Weinberg
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

4.  PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells.

Authors:  G Castoria; A Migliaccio; A Bilancio; M Di Domenico; A de Falco; M Lombardi; R Fiorentino; L Varricchio; M V Barone; F Auricchio
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

5.  Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes.

Authors:  Colin D Clyne; Caroline J Speed; Jiong Zhou; Evan R Simpson
Journal:  J Biol Chem       Date:  2002-04-01       Impact factor: 5.157

6.  Expression of LRH-1 and SF-1 in the mouse ovary: localization in different cell types correlates with differing function.

Authors:  Margaret M Hinshelwood; Joyce J Repa; John M Shelton; James A Richardson; David J Mangelsdorf; Carole R Mendelson
Journal:  Mol Cell Endocrinol       Date:  2003-09-30       Impact factor: 4.102

7.  Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter.

Authors:  Luigi Cicatiello; Raffaele Addeo; Annarita Sasso; Lucia Altucci; Valeria Belsito Petrizzi; Raphaelle Borgo; Massimo Cancemi; Simona Caporali; Silvana Caristi; Claudio Scafoglio; Diana Teti; Francesco Bresciani; Bruno Perillo; Alessandro Weisz
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

8.  P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor.

Authors:  C McMahon; T Suthiphongchai; J DiRenzo; M E Ewen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

9.  The fetoprotein transcription factor (FTF) gene is essential to embryogenesis and cholesterol homeostasis and is regulated by a DR4 element.

Authors:  Jean-François Paré; Daniel Malenfant; Chantal Courtemanche; Mariève Jacob-Wagner; Sylvie Roy; Denis Allard; Luc Bélanger
Journal:  J Biol Chem       Date:  2004-03-10       Impact factor: 5.157

Review 10.  Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.

Authors:  A Bardin; N Boulle; G Lazennec; F Vignon; P Pujol
Journal:  Endocr Relat Cancer       Date:  2004-09       Impact factor: 5.678

View more
  43 in total

1.  Antidiabetic phospholipid-nuclear receptor complex reveals the mechanism for phospholipid-driven gene regulation.

Authors:  Paul M Musille; Manish Pathak; Janelle L Lauer; William H Hudson; Patrick R Griffin; Eric A Ortlund
Journal:  Nat Struct Mol Biol       Date:  2012-04-15       Impact factor: 15.369

2.  Unique ERalpha cistromes control cell type-specific gene regulation.

Authors:  Susan A Krum; Gustavo A Miranda-Carboni; Mathieu Lupien; Jerome Eeckhoute; Jason S Carroll; Myles Brown
Journal:  Mol Endocrinol       Date:  2008-09-25

3.  Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation.

Authors:  Cindy Benod; Maia V Vinogradova; Natalia Jouravel; Grace E Kim; Robert J Fletterick; Elena P Sablin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

4.  Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.

Authors:  Jean-Sébastien Annicotte; Irena Iankova; Stéphanie Miard; Vanessa Fritz; David Sarruf; Anna Abella; Marie-Laurence Berthe; Danièle Noël; Arnaud Pillon; François Iborra; Pierre Dubus; Thierry Maudelonde; Stéphane Culine; Lluis Fajas
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

5.  Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways.

Authors:  Lizao Chen; Jianming Zheng; Yan Zhang; Luxi Yang; Jiaqi Wang; Jian Ni; Daxiang Cui; Chaoqin Yu; Zailong Cai
Journal:  Mol Ther       Date:  2011-05-24       Impact factor: 11.454

6.  LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer.

Authors:  S Wang; Z Zou; X Luo; Y Mi; H Chang; D Xing
Journal:  Oncogene       Date:  2018-03-16       Impact factor: 9.867

7.  Increased expression of hLRH-1 in human gastric cancer and its implication in tumorigenesis.

Authors:  Shui-Liang Wang; De-Zhu Zheng; Feng-Hua Lan; Xiao-Jun Deng; Jian Zeng; Cheng-Jin Li; Rong Wang; Zhong-Yong Zhu
Journal:  Mol Cell Biochem       Date:  2007-10-20       Impact factor: 3.396

8.  CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance.

Authors:  Carine Chavey; Gwendal Lazennec; Sylviane Lagarrigue; Cyrielle Clapé; Irena Iankova; Jacques Teyssier; Jean-Sébastien Annicotte; Julien Schmidt; Chikage Mataki; Hiroyasu Yamamoto; Rosario Sanches; Anna Guma; Vladimir Stich; Michaela Vitkova; Bénédicte Jardin-Watelet; Eric Renard; Robert Strieter; Antoinette Tuthill; Gôkhan S Hotamisligil; Antonio Vidal-Puig; Antonio Zorzano; Dominique Langin; Lluis Fajas
Journal:  Cell Metab       Date:  2009-04       Impact factor: 27.287

Review 9.  Phospholipid--driven gene regulation.

Authors:  Paul M Musille; Jeffrey A Kohn; Eric A Ortlund
Journal:  FEBS Lett       Date:  2013-01-16       Impact factor: 4.124

10.  Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.

Authors:  M Hauglid Flågeng; L L Haugan Moi; J M Dixon; J Geisler; E A Lien; W R Miller; P E Lønning; G Mellgren
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.